A
Asciminib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Asciminib
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Asciminib 20 mg and 40 mg tablets as monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors.
Asciminib is not recommended for patients with T315I mutation.
Funding status
[R] Asciminib 20 mg and 40 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
[NR] MAF assistance does not apply to asciminib 100 mg tablet.
Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.